Fertility and rheumatic diseases


Authors: L. Procházková
Authors‘ workplace: Revmatologie, II. interní klinika, FN u sv. Anny a LF MU v Brně
Published in: Čes. Revmatol., 26, 2018, No. 2, p. 72-78.
Category: Review Article

Overview

A significant proportion of patients with inflammatory rheumatic diseases is of childbearing age. The question of an impact of the disease on fertility from the perspective of both a patient and his physician is an important point in the management of rheumatic diseases. Impaired fertility in these patients is not uncommon; female rheumatic patients have fewer children compared to the general population. The cause of the reduction of reproductive functions and infertility is multifactorial: it may involve disease activity, the effect of therapy, abortion, but also the psychological consequences of the disease limiting sexual function, or it is a personal decision of the patient. The discussion with the patient should include parenting planning, attempting to suppress the disease activity as effectively as possible, taking into account the possible adverse events of therapy, choosing a safer alternative or adequate protection of the gonadal functions when treating with alkylating agents and, if necessary, early therapy of infertility.

Key words:

Fertility, reproduction, rheumatic diseases, infertility, protection of gonadal function


Sources

1.   Clowse ME, Chakravarty E, Costenbader KH et al. Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012; 64(5): 668–674.

2.   Helland Y, Dagfinrud H, Kvien TK. Perceived influence of health status on sexual activity in RA patients: associations with demographic and disease-related variables. Scand J Rheumatol 2008; 37(3): 194–199.

3.   El Miedany Y, El Gaafary M, El Aroussy N, Youssef S, Ahmed I. Sexual dysfunction in rheumatoid arthritis patients: arthritis and beyond. Clin Rheumatol 2012; 31: 601–606.

4.   Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: social function, relationships and sexual activity. Rhaumatology (Oxford) 2002; 41: 1440–1443.

5.   Healey EL, Haywood KL, Jordan KP, et al.  Ankylosing spondylitis and its impact on sexual relationships. Rheumatology (Oxford) 2009; 48: 1378–1381.

6.   García Morales M, Callejas Rubio JI, Peralta-Ramírez MI, Henares Romero LJ,Ríos Fernández R, Camps García MT, et al. Impaired sexual function in women with systemic lupus erythematosus: a cross-sectional study. Lupus 2013; 22(10): 987–95.

7.   Henes M, Froeschlin J, Taran FA, Brucker S, Rall KK, Xenitidis T, et al. Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: impact of rheumatoid arthritis, Behçet‘s disease and spondyloarthritis on anti-Müllerian hormone levels. Rheumatology (Oxford) 2015; 54(9): 1709–12.

8.   Østensen M. New insights into sexual functioning and fertility in rheumatic diseases. Best Pract Res Clin Rheumatol 2004; 18: 219–232.

9.   Brouwer J, Hazes JM, Laven JS, Dolhain RJ. Fertility in women with rheumatoid arthritis: influence of disease activity and medication. Ann Rheum Dis 2015; 74(10): 1836–41.

10. Wallenius M, Skomsvoll JF, Irgens LM, Salvesen KÅ, Nordvåg BY, Koldingsnes W, et al. Fertility in women with chronic inflammatory arthritides. Rheumatology (Oxford) 2011; 50(6): 1162–7.

11. Barbakadze L, Kristesashvili J, Khonelidze N, Tsagareishvili G. The correlations of anti-Müllerian hormone, follicle-stimulating hormone and antral follicle count in different age groups of infertile women. Int J Fertil Steril 2015; 8(4): 393–8.

12. Provost M, Eaton JL, Clowse ME. Fertility and infertility in rheumatoid arthritis. Curr Opin Rheumatol 2014; 26(3): 308–14.

13. Brouwer J, Laven JS, Hazes JM, Schipper I, Dolhain RJ. Levels of serum anti-Müllerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013; 65(9): 1534–8.

14. Morel N, Bachelot A, Chakhtoura Z, Ghillani-Dalbin P, Amoura Z, Galicier L, et al. Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab 2013; 98(9): 3785–92.

15. Gasparin AA, Souza L, Siebert M, Xavier RM, Chakr RM, Palominos PE, et al. Assessment of anti-Müllerian hormone levels in premenopausal patients with systemic lupus erythematosus. Lupus 2016; 25(3): 227–32.

16. Jawaheer D, Zhu J L, Nohr EA, Olsen J. Time to pregnancy among women with rheumatoid arthritis.  Arthritis Rheum 2011; 63: 1517–1521.

17. Tengstrand B, Carlström K, Hafström IJ. Gonadal hormones in men with rheumatoid arthritis – from onset through 2 years. Rheumatol. 2009; 36, 887–892.

18. Nukumizu LA, Gonçalves Saad C, Ostensen M, Almeida BP, Cocuzza M, Gonçalves C et al. Gonadal function in male patients with ankylosing spondylitis. Scand J Rheumatol. 2012; 41(6): 476–81.

19. Almeida BP, Saad CG, Souza FH, Moraes JC, Nukumizu LA, Viana VS, et al. Testicular Sertoli cell function in ankylosing spondylitis. Clin Rheumatol 2013; 32(7): 1075–9.

20. Soares PM, Borba EF, Bonfa E, Hallak J, Corrêa AL, Silva CA. Gonad evaluation in male systemic lupus erythematosus. Arthritis Rheum 2007; 56(7): 2352–61.

21. Shiraishi Y, Shibahara H, Koriyama J, Hirano Y, Okazaki H, Minota S, et al. Incidence of antisperm antibodies in males with systemic autoimmune diseases. Am J Reprod Immunol 2009; 61(3): 183–9.

22. Hill MJ, Cooper JC, Levy G, Alford C, Richter KS, DeCherney AH, et al. Ovarian reserve and subsequent assisted reproduction outcomes after methotrexate therapy for ectopic pregnancy or pregnancy of unknown location. Fertil Steril 2014; 101(2): 413–9.

23. Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Shechtman S, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol 2014; 66: 1101–1110.

24. Pandhi D, Gupta R, Singal A. Gynaecomastia with oligospermia: an unusual complication of low-dose methotrexate for pustular psoriasis. Clin Exp Dermatol 2006; 31(1): 138–40.

25. Villiger PM, Caliezi G, Cottin V, Förger F, Senn A, Østensen M. Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis. 2010; 69(10): 1842–4.

26. Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, Meister R, Schaefer C. No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study. Rheumatology (Oxford) 2014; 53(4): 757–63.

27. Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K, Arthanari S, et al. BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding – Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 2016; 55(9): 1693–7.

28. Birnie GG, McLeod TI, Watkinson G. Incidence of sulphasalazine-induced male infertility. Gut 1981; 22: 452–455.

29. Riley SA, Lecarpentier J, Mani V, Goodman MJ, Mandal BK, Turnberg LA. Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution. Gut 1987; 28(8): 1008–12.

30. Leroy C, Rigot JM, Leroy M, Decanter C, Le Mapihan K, Parent A et al. Immunosuppressive drugs and fertility. Orphanet J Rare Dis 2015; 10: 136.

31. Hickman RA, Gordon C. Causes and management of infertility in systemic lupus erythematosus. Rheumatology (Oxford) 2011; 50(9): 1551–8.

32. Akawatcharangura P, Taechakraichana N, Osiri M. Prevalence of premature ovarian failure in systemic lupus erythematosus patients treated with immunosuppressive agents in Thailand. Lupus 2016; 25(4): 436–44.

33. Boumpas DT, Austin HA 3rd, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119(5): 366–9.

34. Mok CC, Chan PT, To CH. Anti-Müllerian hormone and ovarian reserve in systemic lupus erythematosus. Arthritis Rheum 2013; 65(1): 206–10.

35. Whirledge S, Cidlowski JA. Glucocorticoids, stress, and fertility. Minerva Endocrinol. 2010; 35(2): 109–25.

36. Silva CA, Bonfa E, Østensen M. Maintenance of fertility in patients with rheumatic diseases needing antiinflammatory and immunosuppressive drugs. Arthritis Care Res (Hoboken) 2010; 62(12): 1682–90.

37. Shin T, Okada H. Infertility in men with inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016; 7: 361–369.

38. Micu MC, Micu R, Ostensen M. Luteinized unruptured follicle syndrome increased by inactive disease and selective cyclooxygenase 2 inhibitors in women with inflammatory arthropathies. Arthritis Care Res (Hoboken) 2011; 63(9): 1334–8.

39. Martini AC, Molina RI, Tissera AD, Ruiz RD, Fiol de Cuneo M. Analysis of semen from patients chronically treated with low or moderate doses of aspirin-like drugs. Fertil Steril 2003; 80(1): 221–2.

40. Levine AB, Lockshin MD. Assisted reproductive technology in SLE and APS. Lupus 2014; 23(12): 1239–41.

41. Clowse ME, Behera MA, Anders CK, Copland S, Coffman CJ, Leppert PC, Bastian LA. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 2009; 18(3): 311–9.

42. Chen H, Li J, Cui T, Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 2011: CD008018.

43. Sammaritano L. Contraception in Patients with Rheumatic Disease. Rheum Dis Clin N Am 2017; 43: 173–188.

44. Stringer EM, Kaseba C, Levy J, Sinkala M, Goldenberg RL, Chi BH, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 2007; 197(2): 144 e1–8.

45. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353(24): 2550–8.

46. Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc AH, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005; 353(24): 2539–49.

47. Farr SL, Folger SG, Paulen ME, Curtis KM. Safety of contraceptive methods for women with rheumatoid arthritis: a systematic review. Contraception 2010; 82(1): 64–71.

48. Amy JJ, Tripathi V. Contraception for women: an evidence-based overview. Brit Med J 2009; 339(7): b2895

Labels
Dermatology & STDs Paediatric rheumatology Rheumatology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account